- Home
- HMR vs MIRA Comparison
HMR vs MIRA Comparison
Compare HMR & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HMR | MIRA |
|---|---|---|
| Founded | 1984 | 2020 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.4M | 56.1M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | HMR | MIRA |
|---|---|---|
| Price | $0.93 | $1.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 38.1K | ★ 173.3K |
| Earning Date | 05-06-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,086,264.00 | N/A |
| Revenue This Year | $52.26 | N/A |
| Revenue Next Year | $45.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.41 | N/A |
| 52 Week Low | $0.76 | $0.73 |
| 52 Week High | $10.04 | $2.45 |
Technical Indicators
Market Signals| Indicator | HMR | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout HMR Heidmar Maritime Holdings Corp.
Heidmar Maritime Holdings Corp is an asset-light tanker pool, and commercial and technical management company. The company is a fast-growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. The company has also recently expanded its business to offer pool management of dry bulk vessels and technical management. The company generates maximum revenue from Singapore.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.